A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China

NCT03736226 · tracked via the Priya Life Science China tracker

Sponsor

Boston Scientific Corporation

Phase

Observational

Started

2019-07-30

Last updated

2026-08-27

Condition(s) studied

Cardiovascular Diseases

Investigational drug(s) / intervention(s)

SYNERGYTM Stent System

SYNERGYTM Stent System: no intervention design in the study

Study summary

A prospective, observational, single-arm, open-label, multicenter, post-approval study. To compile real-world clinical outcomes data for the SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGYTM Stent System) in real-world clinical practice in China.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * • Subject must be at least 18 years of age * Subject understands and provides written informed consent * Subject who is clinically indicated and will have an attempt of at least one SYNERGYTM stent OR Subject who is clinically indicated and was implanted with at least one SYNERGYTM stent * Subject is willing to comply with all protocol-required follow-up evaluation Exclusion Criteria: * Exclusion criteria are not required in this study which is an "all comers" study.

Primary outcome measure(s)

MACE rate — 12 months
endpoints will be assessed post stent implant

Trial sites (1)

Facility	City	Region	Status
Zhongshan Hospital Fudan University	Shanghai	Shanghai Municipality

More Boston Scientific Corporation trials in China

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions Recruiting

Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') Recruiting

cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia Active, not recruiting

A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism Recruiting

IT Matters: The Erectile Restoration Registry Enrolling by invitation

Other trials for the same condition

The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management Recruiting

Cohort in Qianwan New District, Ningbo Recruiting

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III) Recruiting

Rehabilitation Intervention for COPD Combined With Cardiovascular and Cerebrovascular Diseases Recruiting

Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03736226 on ClinicalTrials.gov ↗ ← All trials in China